Natriuretic Peptide's Headache Inducing Characteristics and Effects on the Cerebral Blood Flow
Not Applicable
Completed
- Conditions
- HeadacheMigraine
- Interventions
- Drug: Natriuretic peptides
- Registration Number
- NCT01637662
- Lead Sponsor
- Danish Headache Center
- Brief Summary
To investigate headache score and accompanying symptoms during and after infusion of the natriuretic peptides.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
- Healthy volunteers
- Aged 18-40
- 50-100 kg
- Fertile women must use safe contraceptives (IUD, oral contraceptives, surgical sterilisation and long lasting gestagen.
Exclusion Criteria
- Tension type headache more than once/month
- Other primary headaches
- Daily medication except contraceptives
- Drug taken within 4 times the halflife for the specific drug except contraceptives
- Pregnant or lactating women
- Exposure to radiation within the last year
- Headache within the last 24 hours before start of trial
- Hypertension
- Hypotension
- Respiratory or cardiac disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Healthy subjects Natriuretic peptides -
- Primary Outcome Measures
Name Time Method Headache intensity, mean velocity of blood flow in the middle cerebral artery (VmeanMCA), superfical temporal artery diameter, PetCO2, adverse events and vital signs were recorded at T-10, T0 and then every 10 min until 120 min after start of infusion. Every 10 min.
- Secondary Outcome Measures
Name Time Method All subjects were asked to complete a headache diary every hour until 10 h after the discharge. The diary included headache characteristics and accompanying symptoms according to the International Headache Society (IHS 2004) 10 hours after discharge
Trial Locations
- Locations (1)
Danish Headache Center
🇩🇰Copenhagen, Glostrup, Denmark